Veidlapa Nr. M-3 (8)
Studiju kursa apraksts
Hroniska limfoleikoze un citas limfoproliferatīvās leikozes
Kursa kods
RHE_058
Zinātnes nozare
Klīniskā medicīna
Kredītpunkti (ECTS)
7,00
Mērķauditorija
Ārstniecība
LKI
8. līmenis
Studiju kursa īstenotājs
Kursa vadītājs
Sandra Lejniece
Rezidentūras specialitāte
Specialitāte
Hematologs
Vadītājs
Sandra Lejniece
Kontaktinformācija
-
Par studiju kursu
Mērķis
Nodrošināt teorētisko zināšanu un praktisko iemaņu apguvi un pilnveidošanu par hronisku limfoleikozi un citām limfoproliferatīvām leikozēm atbilstoši hematoloģijas specialitātes prasībām, lai ārstu sagatavotu sertifikācijai hematoloģijas specialitātē.
Studiju rezultāti
Zināšanas
1.- Zinās par hronisku limfoleikozi, to cēloņiem, patoģenēzi, klīnisko ainu, laboratoriskām izmaiņām, komplikācijām, ārstēšanu, prognozi; - Zinās par hronisku prolimfocitāru leikozi, matšūnu leikozi, Rihtera sindromu. - Zinās par monoklonālu B-šūnu limfocitozi.
Prasmes
1.- Pratīs diagnosticēt un ārstēt hroniskas limfoleikozes un limfoproliferatīvas leikozes slimniekus.
Kompetences
1.Hroniskas limfoleikozes un limfoproliferatīvu leikožu slimnieku diagnostika un ārstēšana.
Vērtēšana
Patstāvīgais darbs
|
Virsraksts
|
% no gala vērtējuma
|
Vērtējums
|
|---|---|---|
|
1.
Patstāvīgais darbs |
-
|
-
|
|
1. Patstāvīgi studē ar kursa tēmām saistīto literatūru;
2. Patstāvīgi gatavojas semināriem;
3. Patstāvīgi veic slimību anamnēzes datu apkopošanu, pacienta objektīvu izmeklēšanu, formulē primero diagnozi, kas tiek apspriesta ar pasniedzēju;
4. Iepazīstas un analizē medicīnisko dokumentāciju;
5. Aizpilda medicīnisko dokumentāciju;
6. Patstāvīgi izpilda sertificētā speciālista norādījumus.
|
||
Pārbaudījums
|
Virsraksts
|
% no gala vērtējuma
|
Vērtējums
|
|---|---|---|
|
1.
Pārbaudījums |
-
|
-
|
|
Obligāts semināru (100%) apmeklējums un praktiskā darba (100%) veikums katrā studiju kursā.
|
||
Studiju kursa tēmu plāns
PILNA LAIKA
1. daļa
-
Seminārs
|
Modalitāte
|
Norises vieta
|
|
|---|---|---|
|
-
|
-
|
Tēmas
|
Hroniska limfoleikoze – cēloņi, patoģenēze, klīniskā aina, laboratoriskās izmaiņas, komplikācijas, ārstēšana, prognoze.
|
-
Seminārs
|
Modalitāte
|
Norises vieta
|
|
|---|---|---|
|
-
|
-
|
Tēmas
|
Hroniska prolimfocitāra leikozes. Matšūnu leikoze. Transformācija Rihtera sindromā. Monoklonāla B-šūnu limfocitoze.
|
Kopā kredītpunkti (ECTS):
7,00
Semināru skaits:
2
Ilgums (nedēļās):
5
Gala pārbaudījums:
Eksāmens rezidentūrā (Teorija un prakse)
Bibliogrāfija
Obligātā literatūra
1.
Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000. PMID:11136261
2.
Goldin LR, Landgren O, Marti GE et al.: Familial aspects of chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis (MBL) and related lymphomas. Eur J Clin Med Oncol 2:119-216, 2010. PMID:21191471
3.
Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-204, 1981. PMID:7237385
4.
Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975. PMID:1139039
5.
Allegra A, Musolino C, Tonacci A, Pioggia G, Casciaro M, Gangemi S. Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role. Cancers (Basel). 2020 Feb 24;12(2):524. doi: 10.3390/cancers12020524. PMID: 32102441; PMCID: PMC7072434.
6.
Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica. 2020 Sep 1;105(9):2205-2217. doi: 10.3324/haematol.2019.236000. PMID: 33054046; PMCID: PMC7556519.
7.
Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta. 2016 Mar;1863(3):401-413. doi: 10.1016/j.bbamcr.2015.07.009. Epub 2015 Jul 17. PMID: 26193078; PMCID: PMC4715999.
8.
Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 Jan 19;3:16096. doi: 10.1038/nrdp.2016.96. PMID: 28102226; PMCID: PMC5336551.
9.
Campo E, Cymbalista F, Ghia P, Jäger U, Pospisilova S, Rosenquist R, Schuh A, Stilgenbauer S. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018 Dec;103(12):1956-1968. doi: 10.3324/haematol.2018.187583. Epub 2018 Nov 15. PMID: 30442727; PMCID: PMC6269313.
10.
Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 1;112(5):1923-30. doi: 10.1182/blood-2007-05-092882. Epub 2008 Jun 24. PMID: 18577710; PMCID: PMC2518894.
11.
Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127:2672.
12.
Dreger P, Schetelig J, Andersen N et al: Managing high-risk chronic lymphocytic leukemia during transition to a new treatment era: Stem cell transplantation or novel agents. A position statement of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). Submitted.
Citi informācijas avoti
1.
Fischer K, Cramer P, Busch R, et al: Bendamustine combined with rituximab in patients with relapsed and/ or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29:3559-3666, 2011. DOI:10.1200/JCO.2010.33.8061
2.
Dreger P, Döhner H, Ritgen M et al: Allogeneic stem transplantation provides durable disease control in patients with chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116:2438-2447, 2010. DOI:10.1182/blood-2010-03-275420
3.
Raanani P, Gafter-Gvili A, Paul M et al.: Immunoglobulin prophylaxis in hematologic malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev CD006501, 2008. DOI:10.1002/14651858.CD006501.pub2
4.
Byrd JC, Furman RR, Coutre SE, at al: Ibrutinib Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32-42, 2013. DOI:10.1056/NEJMoa1215637
5.
Hodgson K, Ferrer G, Pereira A et al.: Autoimmune cytopenia in chronic lymphocytic leukemia: diagnosis and treatment. Brit J Haematol 154:14-22, 2011. DOI:10.1111/j.1365-2141.2011.08707.x
6.
Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 139:809-819, 2007. DOI:10.1111/j.1365-2141.2007.06856.x
7.
Oscier D, Else M, Matutes E, Morilla R, Strefford JC, Catovsky D The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial Br J Haematol. 2016 Sep; 174(5): 767–775. Published online 2016 May 6. doi: 10.1111/bjh.14132
8.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391-2405. https://doi.org/10.1182/blood-2016-03-643544
9.
Eichhorst BF, Busch R, Stilgenbauer S, et al. No clinical benefit for frontline therapy with fludarabine in comparison to chlorambucil in elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382-3391, 2009. DOI:10.1182/blood-2009-02-206185
10.
Goede V, Fischer K, Busch R, et al: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101-1110, 2014. DOI:10.1056/NEJMoa1313984
11.
Fischer K, Cramer P, Busch R, et al: Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30:3209-3216, 2012. DOI:10.1200/JCO.2011.39.2688
12.
Knauf WU, Lissichkov, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384, 2009. DOI:10.1200/JCO.2008.20.8389
13.
Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-Line Treatment with Fludarabine (F), cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group. Lancet 376:1164-1174, 2010. DOI:10.1016/S0140-6736(10)61381-5
14.
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008. DOI:10.1182/blood-2007-06-093906
15.
Rawstron AC, Bennett FL, O’Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia (CLL). N Engl J Med 359:575-583, 2008. DOI:10.1056/NEJMoa075290
16.
Burger JA, Gribben JG: The microenvironment in chronic lymphocytic leukemia and other B cell malignancies: insight into disease biology and targeted therapies. Semin Cancer Biol 24:71-81, 2014. DOI:10.1016/j.semcancer.2013.08.011
17.
Schetelig J, van Biezen A, Brand R, et al: Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 26:5094-5100, 2008. DOI:10.1200/JCO.2008.16.2982
18.
Stilgenbauer S, Zenz T, Winkler D, et al: Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27:3994-4001, 2009. DOI:10.1200/JCO.2008.21.1128
19.
Byrd JC, Brown JR, O’Brien S, et al: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213-223, 2014. DOI: 10.1056/NEJMoa1400376
20.
Furman RR, Sharman JP, Coutre SE, et al: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997-1007, 2014. DOI:10.1056/NEJMoa1315226